Preclinical Evaluation of Hematoporphyrin Derivative for the Treatment of Intraocular Tumors: A Preliminary Report
Treatment modalities such as external beam radiation therapy, cobalt plaques, photocoagulation or cryotherapy for preservation of useful vision in patients with ocular tumors offer only limited success. In many cases enucleation is necessary in order to prevent tumor spread (1). The accessibility of intraocular tumors to visible light and the excellent optical properties of the eye suggest that hemato-porphyrin derivative photoradiation therapy (HPD PRT) may prove to be an important advancement in the successful management of intraocular and periocular malignancies. Due to the extreme sensitivity of the eye to light and the possible loss of vision resulting from non-repairable damage to normal ocular structures, we are performing preclinical studies designed to evaluate the efficacy of HPD PRT as a primary clinical modality for treating ocular tumors.
KeywordsAnterior Chamber Fluorescein Angiography Preclinical Evaluation Acute Toxicity Study Choroidal Malignant Melanoma
Unable to display preview. Download preview PDF.
- 1.D.J. Apple and F.C. Blodi, Uveal Melanocytic Tumors — A Grouping According to Phases of Growth and Prognosis with Comments on Current Theories of Nonenucleation Treatment, in “Advances Regarding the Pathogenesis and Treatment of Ocular Tumors”, D.M. Albert and R.R. Weichselbaum, eds, pp. 33, Little, Brown and Company, 1980.Google Scholar